Slide 1: Q4 FY23 Investor Presentation
Q4 FY23 Investor Presentation May 2023 B I O C O N L I M I T E D 1
Slide 2: Core Values
Biocon is a technology-enabled, future-ready, global biopharmaceuticals leader driven by an unwavering purpose to enhance healthcare worldwide through high- quality, affordable therapies that can lower costs, increase access and improve treatment outcomes. Value Creation through Innovation & Differe
Slide 3: Biocon at a Glance
Biocon at a Glance ₹ 11,550 Cr | ~15,000+ Rank #8 Among Top 10 Global Total Employees* $ ~1.4 bn Biotech Employers** Revenue* 1,300+ 100+ 7 Patents* cGMP approvals from International regulatory agencies Manufacturing units* 120+ 15 of top 20 Top 28 Countries where our pharma companies Products withi
Slide 4: Building Biocon
Building Biocon B I O C O N L I M I T E D 44
Slide 5: Biocon: One Company, with multiple value propositions across its verticals
Biocon: One Company, with multiple value propositions across its verticals From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality & affordable healthcare products & services, globally Ensuring access through quality, affordability, reliability ▪ Lead
Slide 6: Generics Business at a Glance
Generics Business at a Glance Presence in R&D team of 5 90+ 750+ 100+ State-of-the-art cGMP approvals 450+ global countries including U.S., facilities received from international scientists customer reach Europe & large EMs regulatory agencies Portfolio comprises 90+ 500+ 300+ 50+ APIs Generic DMFs
Slide 7: Generics: API & Formulations - Growth Levers
Generics : API & Formulations - Growth Levers Strengths built over the years Product Portfolio Expansion Capacities Additions & Expansion • Expertise in fermentation technology, large scale • API - Expanding portfolio beyond fermentation and • Immunosuppressants API (Visakhapatnam) chromatography &
Slide 8: Generics: Our Key APIs and Formulations
Generics : Our Key APIs and Formulations APIs* F O R M U L AT I O N S Therapeutic Molecule Therapeutic Area Molecule Therapeutic Area Molecule US Dev. Markets: ex-US MoW1 Area Tacrolimus Rosuvastatin Calcium EU Apixaban Simvastatin Atorvastatin Mycophenolate Mofetil Atorvastatin Dabigatran Cardiovas
Slide 9: Biosimilars Business at a Glance
Biosimilars Business at a Glance Global reach in Diverse global Top 15 25+ 100+ in global cGMP approvals talent pool of countries including U.S., biomanufacturing received from key regulatory 5,500+ Europe and EMs capacity agencies people 965+ Portfolio comprises 8 patents granted 20 biosimilars Com
Slide 10: Biosimilars: Unique, fully integrated capabilities from lab to market
Biosimilars: Unique, fully integrated capabilities from lab to market Research & Development Global Scale Manufacturing Commercialization Process & Product Development Mammalian & microbial tech platforms Commercial footprint in 100+ countries 3 Manufacturing Sites Analytical & Bioanalytical Capabil
Slide 11: Biosimilars: Leading global player with a strong track record of success
Biosimilars: Leading global player with a strong track record of success Built on a 40+ year legacy of cutting-edge science …with a strong track record in an attractive market • Invested >$1B in biosimilars ahead of its peers to build • Achieved many ‘firsts’ in the industry - first to receive exper
Slide 12: Biosimilars: Acquisition of Viatris' global biosimilars business
Biosimilars: Acquisition of Viatris’ global biosimilars business Provides full Accelerates BBL’s ownership direct entry in of collaboration many markets assets, as well as across AMs & EMs, Viatris’ rights for in- takes us closer to licensed biosimilars >USD 3B+ Acquisition - Amongst Largest patient
Slide 13: Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars
Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars Oncology Immunology Ophthalmology Bone Health Diabetes Others Vaccines Therapy Area • Pegfilgrastim • Adalimumab • RHI Approved or • Trastuzumab • Etanercept • Glargine U100 Commercial • Bevacizumab • Aspart • Denosumab • Ustek
Slide 14: Biosimilars: Portfolio offers multiple shots on goal to drive sustainable growth
Biosimilars: Portfolio offers multiple shots on goal to drive sustainable growth BIOCON BIOLOGICS GROWTH DRIVERS Today < 2 years 2-4 years >4 years - Pegfilgrastim - Bevacizumab (US) - Aflibercept - Pertuzumab - Trastuzumab - Aspart (US) - Denosumab - Glargine 300 IU - Bevacizumab - Adalimumab (US)
Slide 15: Novel Molecules: Itolizumab
Novel Molecules : Itolizumab Pushing to deliver impactful innovations in collaboration with Equillium Inc. ✓ Pivotal Phase III Study initiated in Mar ’22 for use in First-Line treatment of Acute GVHD; Acute Graft- patient dosing initiated Itolizumab Versus-Host ✓ European Commission granted Orphan D
Slide 16: Novel Molecules: Bicara Therapeutics - Dual Action | Dual Impact
Novel Molecules : Bicara Therapeutics* - Dual Action | Dual Impact The precision of targeted therapies | The power of tumor modulators ✓ Lead product candidate, BCA101 (EGFR / TGF-β-trap) demonstrates tumor target engagement and clinical activity ✓ Monotherapy activity in difficult to treat post-pem
Slide 17: Research Services: Syngene's broad capabilities spanning the value chain
Research Services : Syngene’s broad capabilities, spanning the value chain, facilitate integration to capture additional benefits for clients Research business Development and Manufacturing business Discovery Services Dedicated R&D Centres Development Services Manufacturing Services Flexible Platfor
Slide 18: Research Services (Syngene): Key Growth Levers
Research Services (Syngene) : Key Growth Levers Opportunities for service Solutions-based approach in Extension and expansion of Development Services and clinical Scaling up Manufacturing Services Dedicated Centres integration in Discovery Services supplies • Flexible platform solutions with • Integ
Slide 19: Q4 & Full Year FY23 Highlights
Q4 & Full Year FY23 Highlights B I O C O N L I M I T E D 19 19
Slide 20: Financial Highlights: Q4 FY23
Financial Highlights: Q4 FY23 Consolidated (in ₹ Cr.) Q4 FY23 Q4 FY22 YoY % Biosimilars +114% | Research +31% | Generics - Total Revenue 3,929 2,476 59 Includes ₹109 Cr from Bicara stake dilution gain Core EBITDA1 1,260 809 56 Growth driven by Biosimilars & Research services % Margin 35% 33% Net R&D
Slide 21: Financial Highlights: FY23 (1/2)
Financial Highlights: FY23 (1/2) Consolidated (in ₹ Cr.) FY23 FY22 YoY % Biosimilars +61% | Research +23% | Generics +13% Total Revenue 11,550 8,397 38 Includes ₹217 Cr from Bicara stake dilution gain Core EBITDA1 3,807 2,669 43 Growth driven by Biosimilars & Research services % Margin 34% 32% Net R
Slide 22: Financial Highlights: FY23 (2/2)
Financial Highlights: FY23 (2/2) Consolidated (in ₹ Cr.) FY23 FY22 YoY % Net Profit 787 722 9 (before exceptional charge) Exceptional items during FY23: Exceptional Items • Deal related expenses of the Viatris transaction (net of tax and minority interest) (324) 74 • MAT credit balance charge on ado
Slide 23: Generics: Q4 & full year FY23 Update
Generics: Q4 & full year FY23 Update K E Y H I G H L I G H T S In INR Cr Q4 FY23 Q4 FY22 YoY % Revenue growth for the quarter muted mainly due to product mix, margins lower due to price erosion in base business products Segment Revenue 717 717 0 Delivered revenue in-line with guidance of for the ful
Slide 24: Biosimilars: Q4 and full year FY23 Update
Biosimilars: Q4 and full year FY23 Update K E Y H I G H L I G H T S In INR Cr Q4 FY23 Q4 FY22 YoY % Revenue 2,102 982 114 Q4 FY23 is the first full quarter with consolidated financials having both base and acquired business; guidance met Core EBITDA 742 382 95 % of revenue 39% 39% R&D investments in
Slide 25: Novels: Q4 FY23 update
Novels : Q4 FY23 update K E Y H I G H L I G H T S Patient enrolment ramped up in the pivotal Phase III clinical study of itolizumab in patients with aGVHD* (EQUATOR study) Pivotal Phase 1b clinical study of itolizumab for Lupus Nephritis (EQUALISE study) remains on track, top line data expected in 1
Slide 26: Research Services: Q4 & full year FY23 update
Research Services: Q4 & full year FY23 update K E Y H I G H L I G H T S In INR Cr Q4 FY23 Q4 FY22 YoY % Biggest quarter ever. Strong growth with positive performances Segment Revenue 994 758 31 across all four divisions PBT 231 179 29% The growth of Discovery Services and Dedicated Centers remained
Slide 27: Environment, Social, Governance
Environment, Social, Governance B I O C O N L I M I T E D 27 27
Slide 28: ESG: A Culture of Purpose, Ethics & Equity
ESG: A Culture of Purpose, Ethics & Equity Going beyond financials to have a positive impact Recognitions Our ESG Strategy Pillars Published 1st GRI aligned ESG & BRSR Report for FY22 Improve access to high quality therapeutics to drive ‘Patient Equity’ Improved ESG score of 52, part of Emerging Mar
Slide 29: Annexures
Annexures B I O C O N L I M I T E D 29 29
Slide 30: Biocon's Evolution: Our journey over the last 5 decades
Biocon’s Evolution: Our journey over the last 5 decades Metamorphosis from manufacturer of enzymes to a vertically integrated bio-pharmaceutical player and global CRO & CDMO of global standing. Created tangible differentiators for sustainable growth with focus on research and innovation 1970s-80s 19
Slide 31: With many firsts, Biocon is ahead of the curve
With many firsts, Biocon is ahead of the curve • 1st Indian Life • 1st Clinical Research • 1st company globally to • 1st company in the • 1st Indian Company • 1st anti-CD6 Sciences Company Service Organization get U.S. FDA approval world to develop & to launch a novel monoclonal antibody to get ISO
Slide 32: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 33: Thank You
Thank You B I O C O N L I M I T E D 33 33